Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.60 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.60 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1199388 | 0.90 | NAMPT (0.59) | GRM5GRM1PDK4NAMPTPDE10A | |
| SCHEMBL15756310 | 0.88 | GRM1 (0.55) | GRM5GRM1PDK4NAMPTTNK2 | |
| SCHEMBL12740696 | 0.87 | GRM1 (0.54) | GRM5GRM1PDK4NAMPTTNK2 | |
| SCHEMBL12892530 | 0.87 | GRM5 (0.56) | GRM5GRM1PDK4NAMPTPDE10A | |
| SCHEMBL4670030 | 0.86 | GRM5 (0.51) | GRM5GRM1PDK4NAMPTPDE10A | |
| SCHEMBL23791266 | 0.86 | GRM5 (0.48) | GRM5GRM1PDK4NAMPTGPR119 | |
| SCHEMBL64701 | 0.86 | GRM1 (0.55) | GRM5GRM1PDK4NAMPTTNK2 | |
| SCHEMBL15756312 | 0.86 | GRM1 (0.59) | GRM5GRM1PDK4NAMPTPDE10A | |
| SCHEMBL18009522 | 0.86 | GRM1 (0.53) | GRM5GRM1PDK4NAMPTTNK2 | |
| SCHEMBL29138576 | 0.86 | GRM1 (0.53) | GRM5GRM1PDK4NAMPTTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| US-20240307385-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-19 | — | — | US | disclosed |
| US-11969423-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-04-30 | — | — | US | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| CN-116490186-A | Compounds for targeted degradation of RET | C4医药公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-4192458-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-111225910-B | Novel compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-03-24 | — | — | CN | disclosed |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-12 | — | — | US | disclosed |
| CN-1089760-C | Process for production of 4-substituted-3-halogeno-1, 4-benzoxazepine derivative and salts thereof | SUNTORY LTD (JP) | 2002-08-28 | — | — | CN | disclosed |
| EP-0755930-B1 | BENZOXAZEPINE DERIVATIVES, SALTS THEREOF, AND DRUGS CONTAINING THE SAME | SUNTORY LTD (JP) | 2002-07-31 | — | — | EP | disclosed |
| US-6337397-B1 | A BENZOXAZEPINE DERIVATIVE FOR TREATMENT OF ANXIETY NEUROSIS, PHOBIAS, OBSESSIVE-COMPULSIVE DISORDERS, SCHIZOPHRENIA, POST-CARDIAC TRAUMA STRESS DISORDERS, DEPRESSION DISORDERS, PSYCHOSOMATIC DISORDERS AND OTHER PSYCHONEUROTIC DISORDERS, | SUNTORY LIMITED (JP) | 2002-01-08 | — | — | US | disclosed |
| EP-1087962-A4 | PREPARATION OF HETEROARYL COMPOUNDS | LILLY CO ELI (US) | 2001-10-04 | — | — | EP | disclosed |
| EP-1087962-A1 | PREPARATION OF HETEROARYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-04-04 | — | — | EP | disclosed |
| US-6187769-B1 | Benzoxazepine derivatives and their salts and medicaments containing the same | SUNTORY LIMITED (JP) | 2001-02-13 | — | — | US | disclosed |
| US-6114522-A | DEPROTONIZING A BEZOXAZEPINE DERIVATIVE WITH A BASE, REACTING THE DEPROTONIZED PRODUCT WITH A PHOSPHATE HALIDE TO PRODUCE AN INTERMEDIATE, REACTING INTERMEDIATE WITH A COMPLEX OF HALOGEN AND TRIALKYL OR ARYL PHOSPHINE | SUNTORY LIMITED (JP) | 2000-09-05 | — | — | US | disclosed |
| WO-1999065896-A1 | PREPARATION OF HETEROARYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-12-23 | — | — | WO | disclosed |
| CN-1236363-A | Process for production of 4-substituted-3-halogeno-1, 4-benzoxazepine derivative and salts thereof | SUNTORY LTD (JP) | 1999-11-24 | — | — | CN | disclosed |
| EP-0755930-A1 | BENZOXAZEPINE DERIVATIVES, SALTS THEREOF, AND DRUGS CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1997-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307385-A1 | NOVEL COMPOUNDS | FNTB, SDHA, FDPS | GRM5 4211/4885GRM1 4044/4885PDK4 636/4885 |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | CYP4A22, ALOX5, ALOX15 | GRM5 1092/4885GRM1 2182/4885PDK4 1189/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | GRM5 1092/4885GRM1 2182/4885PDK4 1189/4885 |
| US-11969423-B2 | Compounds | SDHA, SDHB, FDPS | GRM5 3497/4885GRM1 3983/4885PDK4 325/4885 |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | RET, HRAS, RBX1 | GRM5 1848/4885GRM1 1210/4885PDK4 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.